Roche and MOMA Therapeutics Enter $2 Billion Strategic Collaboration to Advance Precision Oncology Target Discovery
MOMA Therapeutics
Targeted ATPase (ATPase) Developer
Roche
Oncology Drug Research, Development, and Manufacturing
January 4,MOMA TherapeuticsAnnouncementWith RocheAchieveStrategic Collaboration and Licensing Agreement,MOMA provides Roche with its proprietary knowledge base platform-KnowledgeBase，Used forIdentification and Development of Novel Drug Targets Playing a Key Role in Cancer Cell Proliferation and Survival。
This collaboration will leverage this platform to discover and target highly dynamic innovative precision oncology targets. In addition, MOMA will receive Roche$66 million upfront payment, Total Other EquityAmountUp to $2 billion。
Roche has been making frequent moves recently.January 2Announced a collaboration with Remix Therapeutics worth up to 1 billion USD,The day before yesterday, it spent another $1.05 billion to introduce the c-MET ADC drug developed by Yilian Biotechnology, entering the antibody-drug conjugate (ADC) field, and now has signed this cancer-focused licensing agreement.
Source: Compiled by the PharmResearch Network team
MOMA Therapeutics Founded in 2020,Dedicated to discovering the next generation of precision medicines by targeting the highly dynamic proteins behind human diseases. The company has integrated groundbreaking scientific advances in biochemistry, biophysics, structural biology, chemistry, computation, and functional genomics to build a knowledgebase platform.Through this platformTargeting Pathogenic TargetsMOMA Therapeutics aims to develop precision medicines for patients with unmet medical needs.
MOMA Therapeutics' Drug Discovery Platform-KnowledgeBaseYesThe Cornerstone of MOMA Innovation, integrating structural-functional analysis, lead compound discovery technologies, and computation-empowered lead optimization.Exploiting a key vulnerability inherent in all enzymes within the molecular machinery class:ItThey rely on well-coordinated, stepwise conformational changes.. To date, MOMA Therapeutics has utilized this customized platform toAccelerate ATPase Target CategoryDrug discovery in this category, which has a large number of genetically validated targets, has been hindered by the extent of dynamic protein motion in the industry's efforts to identify therapeutically viable drugs.
ThisFounded only 3 years agoPrivate company,Last yearMay 10Completed $150 Million Series B Financing，Further develop product opportunities and advance a rich pipeline of precision oncology projects.Was selected for the 2021 Fierce Biotech publicationFierce 15 in 2021List,Currently making every effortBuild a pipeline around proteins.
1.https://momatx.com/
2.https://www.fiercebiotech.com/
Disclaimer: The publication/reposting of this article is solely for the purpose of information dissemination, and does not represent the views of this official account or confirm the authenticity of its content. Any judgment made based on this content will be at your own risk.If there is any infringement, please inform us and we will delete it immediately!
Long press to follow this official account
